Drugs With Semaglutide Linked to Deep Vein Thrombosis and Pulmonary Embolism
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient. Semaglutide is associated with a significantly increased risk of blood clots. Ozempic, Wegovy, and Rybelsus causing deep vein thrombosis (DVT) and pulmonary embolism (PE) as blood clots side effects is a drug safety issue that is not well-known. Rather, blood clots have been overshadowed by gastrointestinal and stomach problems linked to Ozempic, Wegovy, and Rybelsus, such as gastroparesis.
We are looking into possible drug injury lawsuits for patients who developed deep vein thrombosis (DVT) or pulmonary embolism (PE) due to these severe blood clots side effects of semaglutide weight-loss drugs Ozempic, Wegovy, and Rybelsus.
No Warnings About Blood Clots Side Effects
There are no warnings about an increased risk of blood clots side effects in the current drug labels for Ozempic, Wegovy, and Rybelsus. This failure to warn by Novo Nordisk (the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus) is a drug safety issue for two reasons:
- A 2021 medical journal article reported that researchers found semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, increased the risk of deep vein thrombosis (DVT) by 266% in patients with type 2 diabetes.
- The blood clots side effects for Ozempic, Wegovy, and Rybelsus are particularly alarming since patients with type 2 diabetes who are also overweight already have an increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Those two reasons become more clear when taking into consideration this background information about semaglutide weight-loss drugs:
- The FDA approved Ozempic as a Type 2 diabetes treatment, such that Ozempic is being used “off-label” for weight loss;
- Likewise, Rybelsus was approved as Type 2 diabetes treatment so it, too, is being used “off-label” for weight loss; and,
- Only Wegovy was approved by the FDA as a treatment for adult obesity and “indicated” for weight loss, so it is not being used “off-label” for weight loss.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients hospitalized with deep vein thrombosis (DVT) or pulmonary embolism (PE) would be filed against Novo Nordisk for this failure to warn about the blood clots side effects of semaglutide. Those legal cases would not be filed against the patient’s doctor because there were no warnings about an increased risk of blood clots for Ozempic, Wegovy, and Rybelsus.
Free Case Evaluation for Blood Clots Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit a Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Ozempic, Wegovy, and Rybelsus Causing Blood Clots, DVT, PE
A Rybelsus Blood Clots DVT Case
We have been investigating Ozempic, Wegovy, and Rybelsus blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) cases as possible drug injury lawsuits against the pharmaceutical company Novo Nordisk. Starting in or about 2021, Ozempic, Wegovy, and Rybelsus — the three Novo Nordisk semaglutide-containing drugs — have been associated with a significantly increased risk of blood clots. In this post, we point out a recent medical journal article that discusses a Rybelsus blood clots DVT case involving a teenage boy.
To read more of this article, click below:
From the Abstract part of this medical journal article, “Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report”, we get some information about the Rybelsus blood clots DVT case:
We report the case of a 16-year-old male with mild conventional risk factors for thrombosis [overweight body mass index (BMI) and prolonged sedentary behavior] who developed acute left lower extremity deep venous thrombosis (DVT) within two weeks of initiating [Rybelsus (oral semaglutide)] for weight reduction without medical supervision. He presented with progressive leg pain and swelling, and duplex ultrasonography revealed thrombosis of the distal superficial femoral and popliteal veins….
This case suggests a possible association between [Rybelsus (oral semaglutide)] and venous thrombosis in an adolescent, highlighting the need for careful supervision during off-label use.
We have written previously about the Ozempic, Wegovy, and Rybelsus blood clots side effects of deep vein thrombosis (DVT) and pulmonary embolism (PE):
Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus
Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
We can assist individuals with a Rybelsus blood clots DVT case if they submit an online Case Evaluation Form or call us at 910-256-2971.
[Read the article in full at Drug Injury Watch]Earlier articles about blood clots side effects of Ozempic, Wegovy, and Rybelsus:
- Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
Earlier articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic Vision Loss Claims Compensation Payments Made in 2025
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages